Articles

Web domain requests include .Cialis, .Walmart

Indianapolis-based Eli Lilly and Co. and other corporate heavyweights are applying for Web suffixes including .cialis, .walmart and .jpmorgan under a program to expand the number of Internet domain names beyond .com.

Read More

WellPoint rivals to keep parts of health care law

Some of the nation's biggest health insurers will keep some popular parts of President Barack Obama's health care overhaul even if the law fails to survive U.S. Supreme Court scrutiny later this month. Indianapolis-based WellPoint will wait for the court ruling.

Read More

Lilly chases Novo in insulin race

Eli Lilly and Co. announced positive results for an experiemental insulin at the annual American Diabetes Association conference in Philadelphia, but was still upstaged by Denmark-based Novo Nordisk A/S.

Read More

Employers slow to act on health reform

Even though employers expect the U.S. Supreme Court to strike down at least some of the 2010 health reform law later this month, few are actually doing any contingency planning.

Read More

IU research leads to new genetic test

It took the identification of 19 different genes for researchers at the Indiana University School of Medicine to develop a test for a rare form of cancer. But their gene-hunting has paid off, as a Texas-based company announced Monday the test is available for doctors to use.

Read More

Price hikes offset slower health care use

Newly available data from private health insurance plans show that price hikes by hospitals, doctors and drug companies have kept employer spending rising recently even as their employees and dependents have moderated their consumption of health care services.

Read More

Physician buyouts bruising hospitals

As St. Vincent Health has nearly doubled the number of physicians it employs over the past two years, the losses on those practices have mounted. And the same thing is happening at all the major Indianapolis hospital systems, as all have spent the past four years aggressively acquiring physician practices.

Read More

FDA’s $6.4B drug review fee plan passes Senate

The U.S. Senate voted to let regulators collect on a $6.4 billion fee agreement struck with Indianapolis-based Eli Lilly and Co., Medtronic Inc. and other companies to fund reviews of new drugs and medical devices through 2017.

Read More